Bioequivalence Approaches for Highly Variable Drugs and Drug Products
- 22 September 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 25 (1), 237-241
- https://doi.org/10.1007/s11095-007-9434-x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Novel Scaled Average Bioequivalence Limits Based on GMR and Variability ConsiderationsPharmaceutical Research, 2004
- Scaling or wider bioequivalence limits for highly variable drugs and for the special case of CmaxInt. Journal of Clinical Pharmacology and Therapeutics, 2003
- Limits for the scaled average bioequivalence of highly variable drugs and drug products.Pharmaceutical Research, 2003
- Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products.European Journal of Clinical Pharmacology, 2001
- Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug ProductsPharmaceutical Research, 2001
- An Approach for Widening the Bioequivalence Acceptance Limits in the Case of Highly Variable DrugsPharmaceutical Research, 1995
- Dissertation NoticesInternational Bulletin of Missionary Research, 1994
- Bio-international '92, conference on bioavailability, bioequivalence and pharmacokinetic studies: Bad Homburg, Germany, 20–22 May 1992European Journal of Pharmaceutical Sciences, 1993
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987